News

August 30, 2012: NIAID Awards BioAegis Therapeutics’ Scientific Advisor Lester Kobzik $1MM Grant to Further Plasma Gelsolin Research

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 30, 2012) Lester Kobzik M.D., BioAegis Scientific Advisor and collaborator from Harvard School of Public Health, has made important medical discoveries about plasma gelsolin’s role in boosting immune function to target a broad range of pathogens. Dr. Kobzik is pursuing work in secondary pneumonia under a …

August 30, 2012: NIAID Awards BioAegis Therapeutics’ Scientific Advisor Lester Kobzik $1MM Grant to Further Plasma Gelsolin Research Read More »

July 15, 2012: BioAegis Therapeutics Presents to BARDA Scientists for TechWatch Day

Company Requested to Submit White Papers Following IND BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 15, 2012) BioAegis Therapeutics Inc. announced that it has presented its plasma gelsolin technology platform to scientists at the Biological Advanced Research Development Agency (BARDA). Data shared at the meeting demonstrated the ability of plasma to address biological …

July 15, 2012: BioAegis Therapeutics Presents to BARDA Scientists for TechWatch Day Read More »

May 17, 2011: BioAegis Therapeutics Signs Exclusive Option for Human Protein in Clinical Development

Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and …

May 17, 2011: BioAegis Therapeutics Signs Exclusive Option for Human Protein in Clinical Development Read More »